• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Highlighting Deuruxolitinib for Alopecia Areata

Opinion
Video

Panelists discuss how deuruxolitinib, evaluated in the THRIVE-AA1 and THRIVE-AA2 phase 3 trials, differs from previous Janus kinase (JAK) inhibitors in its formulation and efficacy, and why ensuring long-term patient adherence through 24 weeks is crucial for treatment durability and success.

Related Videos
4 experts in this video
4 experts in this video
© 2025 MJH Life Sciences
AJMC®
All rights reserved.